[Sydney, Australia] George Clinical congratulates its parent company, The George Institute for Global Health for securing $12 million from the National Health and Medical Research Council (NHMRC), Australia’s peak funding body for medical research. These grants will support The Institute’s scientific leaders to improve the lives of people living with chronic kidney disease, septic shock and chronic obstructive pulmonary disorder (COPD). There will also be four supported Project Grants and Partnership Projects that will enable researchers to improve the food supply in Australia, and complete a landmark trial in China investigating the link between cardiovascular disease and salt intake.

Professor Anushka Patel, Chief Scientist of The George Institute, highlighted the fact that these results were particularly impressive due to the 30% success rate for the project grants, almost double the national average.

Two of George Clinical’s Scientific Leaders, Professor Christine Jenkins (Respiratory) and Bruce Neal (Metabolic) are deserving of special mention for the potential impact of their research grants.

Professor¬†Christine Jenkins, Head of Respiratory Group, The George Institute –¬†3.5 million for a new approach for treating COPD. Investigating the use of beta-blockers after multiple database reviews and meta-analyses strongly indicated that COPD patients do not suffer adverse lung function consequences

Professor Bruce Neal, Deputy Executive Director, The George Institute –¬†$1.5 million for the Salt Substitute and Stroke Study (SSaSS). Around 21,000 people in rural China have taken part in this Real World Evidence trial to see if a low sodium diet would lead to a reduction in cardiovascular disease. These funds will enable the researchers to complete the five-year trial and collect face-to-face data at the completion of the trial in 2019 and 2020.

“George Clinical congratulates The George Institute for Global Health for being awarded these exciting grants,” Sean Hart, Managing Director USA and Global Head of Late Phase Studies said following the announcement. “George Clinical has really cut out a niche in the pragmatic development and delivery of late phase and real world evidence studies. Our success has very much been intertwined with the success of our scientific leadership. These grants are further evidence of the calibre of our scientific leadership and their ability to develop and deliver pragmatic trial solutions to the highest scientific standards.

Media Enquiries

Matthew Reabold
George Clinical | A division of The George Institute for Global Health
6555 Quince Rd, Suite 503 | Memphis TN 38119 | USA
T +1 760 645 0496 (Direct) | M +1 619-201-0669
E mreabold@georgeclinical.com